NervGen Pharma Stock (NASDAQ:NGEN)

Ownership Financials Chart

Previous Close

$1.87

52W Range

$1.70 - $6.30

50D Avg

$2.88

200D Avg

$3.58

Market Cap

$161.10M

Avg Vol (3M)

$763.29K

Beta

0.69

Div Yield

-

NGEN Company Profile

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

7

IPO Date

Feb 08, 2021

Website

NGEN Performance

NGEN Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-17.33M	$-13.41M	$-16.99M
Net Income	$-16.68M	$-16.89M	$-15.29M
EBITDA	$-16.62M	$-16.78M	$-14.82M
Basic EPS	$-0.25	$-0.28	$-0.29
Diluted EPS	$-0.25	$-0.28	$-0.29

Fiscal year ends in Dec 24 | Currency in USD